August 16, 2018 / 6:53 PM / a year ago

Japan's Eisai gains U.S. approval for liver cancer treatment

Aug 16 (Reuters) - The U.S. Food and Drug Administration on Thursday approved here a therapy by Japan's Eisai Co Ltd for previously untreated patients with a common form of liver cancer.

The oral drug, Lenvima, was jointly developed with Merck & Co and has been approved to treat unresectable hepatocellular carcinoma.

Lenvima has previously been approved to treat kidney cancer and thyroid cancer. (Reporting by Manas Mishra in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below